candida albicans allergen
Trade name: Candin
Allergenapproved
Approved
Nov 27, 1995
Candín is a village and municipality located in the region of El Bierzo. According to the 2010 census (INE), the municipality has a population of 310 inhabitants. — Wikipedia
Clinical trial activity
13 trials · 15 clinical orgs · 1 marketing orgs
Phase 1
7
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 1999 (NCT00006113)
Timeline
1990s
- Nov 27, 1995
Nielsen BioSciences, Inc. — Earliest FDA Approval
- Nov 27, 1995
Nielsen BioSciences, Inc. — NDA Secondary Org
- Nov 27, 1995
Nielsen BioSciences, Inc. — NDA Organization
- Jan 1, 1999
Earliest Phase 2 Sponsor(trial)
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Mechanism of action
- CandidaImmunity, desensitized
Candida immunity, desensitized
Approval history
- approvedNov 27, 1995
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaValle de Ancares ↗
- NCATS4D7G21HDBC ↗
- WikipediaCandín ↗
Also known as
- candida albicans antigen
- candida albicans skin test antigen for cellular hypersensitivity
- candida skin test antigen
- candin
- candin
- candin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05952934 | Phase 2 | Jan 31, 2024 | University of Arkansas |
| NCT05522517 | Phase 1 | Aug 22, 2022 | — |
| NCT05216510 | Phase 1 | Jan 7, 2022 | Premier Research Group, Tonix Pharmaceuticals |
| NCT04611971 | Phase 1 | Oct 27, 2020 | Janssen Pharmaceutica NV |
| NCT04589026 | Phase 1 | Oct 21, 2020 | Janssen Pharmaceutica NV |
| NCT03953196 | Early Phase 1 (Phase 1) | Apr 8, 2019 | Johnson and Johnson |
| NCT02889159 | N/A | Jun 6, 2016 | University of Michigan |
| NCT02393417 | Phase 2 | Mar 31, 2015 | Nielsen BioSciences, Inc. |
| NCT01757392 | Phase 2 | Sep 1, 2012 | Nielsen BioSciences, Inc. |
| NCT01653249 | Phase 1 | Aug 1, 2012 | Hoosier Cancer Research Network, National Cancer Institute (NCI) |
| NCT00953927 | Phase 2 | Jul 1, 2009 | Aeras, South African Tuberculosis Vaccine Initiative (SATVI), University of Cape Town, University of Oxford |
| NCT00569231 | Phase 1 | Feb 1, 2007 | Allermed Laboratories, Hoosier Cancer Research Network |
| NCT00006113 | Phase 2 | Jun 1, 1999 | National Cancer Institute (NCI), University of Southern California |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (15)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hoosier Cancer Research Network | Academic/Hospital | 2 | 2 | 1 | 2007 |
| Janssen Pharmaceutica NV | For profit | 2 | 2 | 1 | 2020 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 1999 |
| Nielsen BioSciences, Inc. | For profit | 2 | 2 | 1 | 2012 |
| Aeras | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Allermed Laboratories | For profit | 1 | 0 | 1 | 2007 |
| Johnson and Johnson | For profit | 1 | 1 | 1 | 2019 |
| Premier Research Group | For profit | 1 | 0 | 1 | 2022 |
| South African Tuberculosis Vaccine Initiative (SATVI) | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Tonix Pharmaceuticals | For profit | 1 | 1 | 1 | 2022 |
| University of Arkansas | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Cape Town | Academic/Hospital | 1 | 0 | 1 | 2009 |
| University of Michigan | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of Oxford | Academic/Hospital | 1 | 0 | 1 | 2009 |
| University of Southern California | Academic/Hospital | 1 | 1 | 1 | 1999 |
15 organizations
Page 1 / 1
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Nielsen BioSciences, Inc. | For profit | NDA2 | Nov 27, 1995 |
| Nielsen BioSciences, Inc. | For profit | NDA | Nov 27, 1995 |